LiraglutideA Review of its Use in the Management of Type 2 Diabetes Mellitus

被引：0
作者：
Caroline M. Perry
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Metformin; Rosiglitazone; Glycaemic Control; Liraglutide; Insulin Glargine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Liraglutide (Victoza®) is a subcutaneously administered glucagon-like peptide-1 (GLP-1) receptor agonist produced by recombinant DNA technology and used as an adjunct to diet and exercise in the treatment of adults with type 2 diabetes mellitus. This article reviews the clinical efficacy and tolerability of liraglutide in adults with type 2 diabetes, and provides a summary of its pharmacological properties. Recently published pharmacoeconomic studies of liraglutide are also reviewed.
引用
收藏
页码：2347 / 2373
页数：26
相关论文
共 240 条
[1]  
Wild S(2004)Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 1047-53
[2]  
Roglic G(2010)A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes Pharmacology 86 44-57
[3]  
Green A(2009)Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 1765-72
[4]  
Fakhoury WK(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 837-53
[5]  
Lereun C(2009)Liraglutide: a review of its use in type 2 diabetes mellitus Drugs 69 1985-2004
[6]  
Wright D(2011)Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents Drugs 71 1675-88
[7]  
Ray KK(2009)Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 473-81
[8]  
Seshasai SR(2011)Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 13 348-56
[9]  
Wijesuriya S(2009)Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med 26 268-78
[10]  
Croom KF(2009)Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2-study Diabetes Care 32 84-90
12345678910